Blockade of chemokine signaling in patients with multiple sclerosis

被引:60
作者
Zipp, F.
Hartung, H-P.
Hillert, J.
Schimrigk, S.
Trebst, C.
Stangel, M.
Infante-Duarte, C.
Jakobs, P.
Wolf, C.
Sandbrink, R.
Pohl, C.
Filippi, M.
机构
[1] Charite Univ Med Berlin, Neurosci Res Ctr, Inst Neuroimmunol, D-10098 Berlin, Germany
[2] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[3] Karolinska Inst, Neurotec Dept, Stockholm, Sweden
[4] Ruhr Univ Bochum, Dept Neurol, St Josef Hosp, D-4630 Bochum, Germany
[5] Sch Med, Dept Neurol, Hannover, Germany
[6] Schering AG, Berlin, Germany
[7] Univ Hosp, Dept Neurol, Bonn, Germany
[8] Univ Milan, HSR, Milan, Italy
[9] Inst Sci, Dept Neurol, Neuroimaging Res Unit, Milan, Italy
关键词
D O I
10.1212/01.wnl.0000244420.68037.86
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The CC chemokine receptor 1 (CCR1), expressed on macrophages and T cells, and its ligands, CCL3 and CCL5, are likely to play a role in MS pathology. In MS plaques, numerous CCR1-positive infiltrating macrophages and microglial cells, especially associated with CCL3, were found. 1 CCR1 has been associated with newly infiltrating monocytes in MS lesions.(2) The degree of leukocyte infiltration into the CNS during experimental autoimmune encephalomyelitis (EAE) was reduced on treatment with a specific CCR1 antagonist.(3) CCR1-deficient mice showed an attenuated EAE course.(4) A small-molecule antagonist of CCR1, BX 471, was able to reduce the severity of EAE(5) and delay heart transplant rejection. 6 Here, we investigated the safety, tolerability, and effects of BX 471, which was developed with a potential for oral therapy.
引用
收藏
页码:1880 / 1883
页数:4
相关论文
共 12 条
[11]  
2-D
[12]   CCR1+/CCR5+mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis [J].
Trebst, C ;
Sorensen, TL ;
Kivisäkk, P ;
Cathcart, MK ;
Hesselgesser, J ;
Horuk, R ;
Sellebjerg, F ;
Lassmann, H ;
Ransohoff, RM .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (05) :1701-1710